amlodipine and Aging
amlodipine has been researched along with Aging in 25 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacodynamics and disposition of amlodipine, a dihydropyridine calcium antagonist, were compared between elderly and young patients with hypertension." | 7.68 | Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ( Abernethy, DR; Gutkowska, J; Winterbottom, LM, 1990) |
| "Amlodipine is a long-acting dihydropyridine-based calcium antagonist developed for use on a once-a-day basis." | 5.27 | The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988) |
| "This study in patients with moderate-to-severe hypertension assessed the efficacy and safety of adding hydrochlorothiazide (HCTZ) 12." | 5.16 | Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. ( Ammentorp, B; Christian Rump, L; Laeis, P; Volpe, M, 2012) |
| "Outpatients with mild hypertension treated with a low dose of amlodipine." | 3.77 | The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension. ( Arima, T; Maeda, T; Makino, N; Oyama, JI; Sasaki, M, 2011) |
| " The independent contribution of hypertension and the overactive renin-angiotensin system to soluble guanylyl cyclase subsensitivity was assessed after normalization of TGR's blood pressure by the Ca(2+)-channel blocker amlodipine or the angiotensin converting enzyme-inhibitor enalapril." | 3.70 | Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats. ( Behrends, S; Huser, L; Jacke, K; Lemmer, B; Witte, K, 2000) |
| "Pharmacodynamics and disposition of amlodipine, a dihydropyridine calcium antagonist, were compared between elderly and young patients with hypertension." | 3.68 | Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ( Abernethy, DR; Gutkowska, J; Winterbottom, LM, 1990) |
| " Amlodipine did not affect cardiac function in the young, and with chronic dosing decreased the heart rate by 3-5 bpm and the cardiac index by 0." | 2.72 | Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release. ( Coletta, E; Leenen, FH; White, R, 2006) |
| " The overall incidence of adverse effects were temporary and extremely limited (2%)." | 2.67 | Middle term evaluation of amlodipine vs nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. ( Feraco, E; Grandinetti, O, 1993) |
| "Amlodipine, a dihydropyridine calcium antagonist, was synthesized in an attempt to develop a compound with a pharmacokinetic profile characteristic of this class, which would also have an increased oral bioavailability and extended clearance time." | 2.38 | The pharmacokinetic profile of amlodipine. ( Abernethy, DR, 1989) |
| ": The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications." | 1.56 | Aging does not impact drug--drug interaction magnitudes with antiretrovirals. ( Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M, 2020) |
| "Amlodipine was measured by liquid chromatography-tandem mass spectrometry." | 1.33 | Population analyses of amlodipine in patients living in the community and patients living in nursing homes. ( Kang, D; Schwartz, JB; Verotta, D, 2006) |
| "Mean amlodipine dose was 0." | 1.31 | Treatment of hypertensive children with amlodipine. ( Bunchman, TE; Flynn, JT; Smoyer, WE, 2000) |
| "Structural features of amlodipine give the molecule physicochemical and pharmacokinetic properties that are unique among calcium antagonists." | 1.28 | Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist. ( Abernethy, DR, 1991) |
| "Amlodipine is a long-acting dihydropyridine-based calcium antagonist developed for use on a once-a-day basis." | 1.27 | The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988) |
| " amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs." | 1.27 | Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. ( Abernethy, DR; Gutkowska, J; Lambert, MD, 1988) |
Research
Studies (25)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Stader, F | 1 |
| Decosterd, L | 1 |
| Stoeckle, M | 1 |
| Cavassini, M | 1 |
| Battegay, M | 1 |
| Saldanha, SA | 1 |
| Marzolini, C | 1 |
| Courlet, P | 1 |
| Li, X | 1 |
| Ma, J | 1 |
| Xu, J | 1 |
| Zhu, D | 1 |
| Li, A | 1 |
| Che, Y | 1 |
| Chen, D | 1 |
| Feng, X | 1 |
| Carter, JM | 1 |
| Irving, AC | 1 |
| Bridges, JP | 1 |
| Jones, BR | 1 |
| Trenson, S | 1 |
| de Ceuninck, M | 1 |
| Lu, J | 1 |
| Liu, F | 2 |
| Chen, F | 1 |
| Jin, Y | 1 |
| Chen, H | 1 |
| Liu, D | 1 |
| Cui, W | 2 |
| Lu, JC | 1 |
| Zhang, HL | 1 |
| Han, M | 1 |
| Liu, DM | 1 |
| Yin, HN | 1 |
| Zhang, K | 1 |
| Du, J | 1 |
| Maeda, T | 1 |
| Oyama, JI | 1 |
| Sasaki, M | 1 |
| Arima, T | 1 |
| Makino, N | 1 |
| Volpe, M | 1 |
| Christian Rump, L | 1 |
| Ammentorp, B | 1 |
| Laeis, P | 1 |
| Civantos, B | 1 |
| Aleixandre, A | 1 |
| Abernethy, DR | 4 |
| Leenen, FH | 1 |
| Coletta, E | 1 |
| White, R | 1 |
| Kang, D | 1 |
| Verotta, D | 1 |
| Schwartz, JB | 1 |
| Palmieri, V | 1 |
| Pini, R | 1 |
| Chiara Cavallini, M | 1 |
| Io, K | 1 |
| Minatoguchi, S | 1 |
| Nishigaki, K | 1 |
| Ojio, S | 1 |
| Tanaka, T | 1 |
| Segawa, T | 1 |
| Matsuo, H | 1 |
| Watanabe, S | 1 |
| Hattori, A | 1 |
| Ueno, K | 1 |
| Ono, H | 1 |
| Hiei, K | 1 |
| Sato, H | 1 |
| Morita, N | 1 |
| Noda, T | 1 |
| Kato, T | 1 |
| Kawasaki, M | 1 |
| Takemura, G | 1 |
| Fujiwara, H | 1 |
| Mason, RP | 1 |
| Lorimer, AR | 1 |
| Anderson, JA | 1 |
| Laher, MS | 1 |
| Davies, J | 1 |
| Lazarus, JH | 1 |
| Taylor, SH | 1 |
| Sanghera, S | 1 |
| Grandinetti, O | 1 |
| Feraco, E | 1 |
| Spratt, KA | 1 |
| Jacke, K | 1 |
| Witte, K | 1 |
| Huser, L | 1 |
| Behrends, S | 1 |
| Lemmer, B | 1 |
| Flynn, JT | 1 |
| Smoyer, WE | 1 |
| Bunchman, TE | 1 |
| Gutkowska, J | 2 |
| Winterbottom, LM | 1 |
| Nayler, WG | 1 |
| Elliott, HL | 1 |
| Meredith, PA | 1 |
| Reid, JL | 1 |
| Faulkner, JK | 1 |
| Lambert, MD | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination[NCT00923091] | Phase 3 | 2,689 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change in Seated Diastolic Blood Pressure (SeDBP).
Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization (NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm HG (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -23.0 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -23.9 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -23.8 |
| Olmesartan/Amlodipine 20mg/5mg | -20.5 |
| Olmesartan/Amlodipine 40mg/5mg | -21.2 |
| Olmesartan/Amlodipine 40mg/10mg | -22.1 |
Change in Seated Diastolic Blood Pressure From Week 18 to Week 22
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -3.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -4.1 |
Change in Seated Diastolic Blood Pressure From Week 22 to Week 26
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -2.7 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | -3.8 |
Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.
(NCT00923091)
Timeframe: Week 26 to week 54
| Intervention | mm Hg (Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/25 Titrated to 40/10/25 | -11.9 |
Change in Seated Systolic Blood Pressure (SeDBP).
(NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -33.2 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -33.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -35.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -35.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -36.2 |
| Olmesartan/Amlodipine 20mg/5mg | -29.9 |
| Olmesartan/Amlodipine 40mg/5mg | -30.4 |
| Olmesartan/Amlodipine 40mg/10mg | -32.8 |
Change in Seated Systolic Blood Pressure From Week 18 to Week 22
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -5.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -6.5 |
Change in Seated Systolic Blood Pressure From Week 22 to Week 26
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -4.5 |
| OLM/AML/HCTZ40/5/12.5mg Nonresponders Randomized to 40/5/25 | -6.7 |
Number of Subjects Reaching Blood Pressure Goal at Week 10
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: baseline to week 10
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 177 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 176 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 197 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 190 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | 179 |
| Olmesartan/Amlodipine 20mg/5mg | 144 |
| Olmesartan/Amlodipine 40mg/5mg | 155 |
| Olmesartan/Amlodipine 40mg/10mg | 166 |
Number of Subjects Reaching Blood Pressure Goal at Week 26
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | Participants (Number) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | 29 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | 47 |
Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 63 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 137 |
Reviews
1 review available for amlodipine and Aging
| Article | Year |
|---|---|
The pharmacokinetic profile of amlodipine.
Topics: Administration, Oral; Aging; Amlodipine; Angina Pectoris; Animals; Biological Availability; Calcium | 1989 |
Trials
5 trials available for amlodipine and Aging
| Article | Year |
|---|---|
Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Adult; Aged; Aging; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Wei | 2006 |
Double-blind comparison of amlodipine and nifedipine retard in the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Aging; Amlodipine; Blood Pressure; Double-Blind Method; Drug Administration Schedule; F | 1994 |
Middle term evaluation of amlodipine vs nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients.
Topics: Aged; Aging; Ambulatory Care; Amlodipine; Blood Pressure; Blood Pressure Determination; Female; Huma | 1993 |
A comparison of the disposition of single oral doses of amlodipine in young and elderly subjects.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; | 1988 |
Other Studies
19 other studies available for amlodipine and Aging
| Article | Year |
|---|---|
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly A | 2020 |
Puerarin and Amlodipine Improvement of D-Galactose-Induced Impairments of Behaviour and Neurogenesis in Mouse Dentate Gyrus: Correlation with Glucocorticoid Receptor Expression.
Topics: Aging; Amlodipine; Animals; Dentate Gyrus; Doublecortin Protein; Drug Therapy, Combination; Female; | 2017 |
The prevalence of ocular lesions associated with hypertension in a population of geriatric cats in Auckland, New Zealand.
Topics: Aging; Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eye Diseases; Hypertension; | 2014 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; At | 2014 |
Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-α, IL-1β and NF-κB inflammatory cytokine networks in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Atorvastatin; C-Reactive Protein; Cardiomegaly; Diastole; Heart Ventricl | 2016 |
Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiom | 2009 |
The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blotting, Southern; Crea | 2011 |
Blood pressure and alpha-vascular reactivity in hypertensive rats treated with amlodipine and dietary Ca.
Topics: Adrenergic alpha-Agonists; Aging; Amlodipine; Animals; Antihypertensive Agents; Azepines; Blood Pres | 2004 |
Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist.
Topics: Adsorption; Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Calcium Channel Blockers; Drug Intera | 1991 |
Population analyses of amlodipine in patients living in the community and patients living in nursing homes.
Topics: Aged; Aged, 80 and over; Aging; Alcohol Drinking; Algorithms; Amlodipine; Calcium Channel Blockers; | 2006 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test.
Topics: Adult; Aged; Aging; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Cohort Studies; Coronary | 2007 |
Probing membrane bilayer interactions of 1,4-dihydropyridine calcium channel blockers. Implications for aging and Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Amlodipine; Brain Chemistry; Calcium Channel Blockers; Cell Membrane | 1994 |
Sex- and age-related antihypertensive effects of amlodipine.
Topics: Aged; Aging; Amlodipine; Antihypertensive Agents; Edema; Female; Humans; Hypertension; Male; Middle | 1997 |
Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats.
Topics: Aging; Amlodipine; Analysis of Variance; Animals; Animals, Genetically Modified; Aorta, Thoracic; Bl | 2000 |
Treatment of hypertensive children with amlodipine.
Topics: Adolescent; Adult; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child, Prescho | 2000 |
Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.
Topics: Administration, Oral; Adult; Aged; Aging; Amlodipine; Atrial Natriuretic Factor; Blood Pressure; Cal | 1990 |
The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload.
Topics: Aging; Amlodipine; Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiomegaly; Coronar | 1988 |
Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics.
Topics: Adult; Aged; Aging; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Half-Life; Hormone | 1988 |